[February 26, 2015]

Research and Markets: Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Pipeline Review 2015 - 20 Companies & 26 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/txd7q4/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strateies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• AbbVie Inc.
• Amarantus Bioscience Holdings, Inc.
• Avineuro Pharmaceuticals, Inc.
• CoMentis, Inc.
• Eli Lilly and Company
• FORUM Pharmaceuticals Inc.
• H. Lundbeck A/S
• Intra-Cellular Therapies, Inc.
• Iproteos S.L.
• Merck & Co., Inc.
• Mithridion, Inc.
• Mnemosyne Pharmaceuticals, Inc.
• Novartis AG
• Pfizer Inc.
• Saniona AB
• Siena Biotech S.p.A.
• SK Biopharmaceuticals Co., Ltd.
• Sunovion Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Upsher-Smith Laboratories, Inc.

Drug Profiles

• A-431404
• ABT-126
• AN-761
• AQW-051
• AUT-1
• AVL-3288
• AVN-211
• BNC-375
• CDD-0304
• DSP-3748
• eltoprazine
• encenicline hydrochloride
• erteberel
• GTS-21
• IPR-001
• IPR-088
• ITI-214
• LUAF-64280
• PNU-120596
• roflumilast
• SEN-15924
• SKL-15508
• Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System
• Small Molecule to Agonize NMDA2B for CIAS
• Small Molecules for Cognitive Impairment Associated with Schizophrenia
• TAK-058

For more information visit http://www.researchandmarkets.com/research/txd7q4/cognitive

[ Back To TMCnet.com's Homepage ]